Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 22
Encontrada(s) 1 página(s)

e-Archivo. Repositorio Institucional de la Universidad Carlos III de Madrid
Publication Artículo científico (JournalArticle)

A clinically compatible drug-screening platform based on organotypic cultures identifies vulnerabilities to prevent and treat brain metastasis

  • Zhu, Lucia
  • Retana, Diana
  • García Gómez, Pedro
  • Álvaro Espinosa, Laura
  • Priego, Neibla
  • Masmudi Martín, Mariam
  • Yebra, Natalia
  • Miarka, Lauritz
  • Hernández Encinas, Elena
  • Blanco Aparicio, Carmen
  • Martínez, Sonia
  • Sobrino, Cecilia
  • Ajenjo, Nuria
  • Artiga, María Jesús
  • Ortega Paino, Eva
  • Torres Ruiz, Raúl
  • Rodríguez Perales, Sandra
  • Soffietti, Riccardo
  • Bertero, Luca
  • Cassoni, Paola
  • Weiss, Tobias
  • Muñoz, Javier
  • Sepúlveda, Juan Manuel
  • González León, Pedro
  • Jiménez Roldán, Luis
  • Moreno, Luis Miguel
  • Esteban, Olga
  • Pérez Núñez, Ángel
  • Hernández Laín, Aurelio
  • Toldos, Óscar
  • Ruano, Yolanda
  • Alcázar, Lucía
  • Blasco, Guillermo
  • Fernández Alen, José
  • Caleiras, Eduardo
  • Lafarga, Miguel
  • Megías, Diego
  • Graña Castro, Osvaldo
  • Nör, Carolina
  • Taylor, Michael D
  • Young, Leonie S
  • Vareslija, Damir
  • Cosgrove, Nicola
  • Couch, Fergus J
  • Cusso Mula, Lorena
  • Desco Menéndez, Manuel
  • Mourón, Silvana
  • Quintela Fandino, Miguel
  • Weller, Michael
  • Pastor, Joaquín
  • Valiente, Manuel
We report a medium-throughput drug-screening platform (METPlatform) based on organotypic cultures that allows to evaluate inhibitors against metastases growing in situ. By applying this approach to the unmet clinical need of brain metastasis, we identified several vulnerabilities. Among them, a blood-brain barrier permeable HSP90 inhibitor showed high potency against mouse and human brain metastases at clinically relevant stages of the disease, including a novel model of local relapse after neurosurgery. Furthermore, in situ proteomic analysis applied to metastases treated with the chaperone inhibitor uncovered a novel molecular program in brain metastasis, which includes biomarkers of poor prognosis and actionable mechanisms of resistance. Our work validates METPlatform as a potent resource for metastasis research integrating drug-screening and unbiased omic approaches that is compatible with human samples. Thus, this clinically relevant strategy is aimed to personalize the management of metastatic disease in the brain and elsewhere., Ministerio de Economía, Industria y Competitividad, Gobierno de España (MINECO). Grant Numbers: SAF2017-89643-R, SAF2014-57243-R, SAF2015-62547-ERC, RYC-2013-13365 FERO. Grant Number: IX FERO Grant for Research in Oncology Fundació la Marató de TV3 (TV3 Marathon Foundation). Grant Number: 141 Melanoma Research Alliance (MRA). Grant Number: 498103 Beug Foundation. Grant Number: Prize for Metastasis Research 2017 Fundación Ramón Areces (Ramón Areces Foundation). Grant Numbers: CIVP19S8163, CIVP20S10662 Worldwide Cancer Research (WCR). Grant Number: 19-0177 H2020-FETOPEN. Grant Number: 828972 Cancer Research Institute (CRI). Grant Number: 54545 Fundación Científica Asociación Española Contra el Cáncer (AECC). Grant Numbers: GCTRA16015SEOA, LABAE19002VALI, POSTD19016PRIE EC | H2020 | H2020 Priority Excellent Science | H2020 European Research Council (ERC). Grant Number: 864759 Sophien-Stiftung zur Förderung der klinischen Krebsforschung Stiftung fur angewandte Krebsforschung Forschungskredit of the University of Zurich. Grant Number: FK-18-054 Betty and David Koetser Foundation for Brain Research Comunidad de Madrid (Community of Madrid). Grant Numbers: S2017/BMD-3867 RENIM-CM, Y2018/NMT-4949 NanoLiver-CM MEC | Instituto de Salud Carlos III (ISCIII). Grant Number: PT20/00044 Ministero dellIstruzione, dellUniversita e della Ricerca-MIUR. Grant Number: D15D18000410001 Science Foundation Ireland Frontiers for the Future Award. Grant Number: 19/FFP/6443 Science Foundation Ireland Strategic Partnership Programme, Precision Oncology Ireland. Grant Number: 18/SPP/3522 Breast Cancer Now. Grant Number: 2019AugSF1310 La Caixa-Severo Ochoa International PhD Program Fellowship. Grant Number: LCF/BQ/SO16/52270014 La Caixa International PhD Program Fellowship-Marie Sklodowska-Curie. Grant Number: LCF/BQ/DI17/11620028 Boehringer Ingelheim Fonds MD fellowship European Molecular Biology Organization. Grant Number: 4053 Foundation for Applied Cancer Research in Zurich
Repisalud
Publication Artículo científico (JournalArticle)

Toward Plasmonic Neural Probes: SERS Detection of Neurotransmitters through Gold-Nanoislands-Decorated Tapered Optical Fibers with Sub-10 nm Gaps.

  • Zheng, Di
  • Pisano, Filippo
  • Collard, Liam
  • Balena, Antonio
  • Pisanello, Marco
  • Spagnolo, Barbara
  • Mach-Batlle, Rosa
  • Tantussi, Francesco
  • Carbone, Luigi
  • De Angelis, Francesco
  • Valiente, Manuel
  • de la Prida, Liset M
  • Ciracì, Cristian
  • De Vittorio, Massimo
  • Pisanello, Ferruccio
Integration of plasmonic nanostructures with fiber-optics-based neural probes enables label-free detection of molecular fingerprints via surface-enhanced Raman spectroscopy (SERS), and it represents a fascinating technological horizon to investigate brain function. However, developing neuroplasmonic probes that can interface with deep brain regions with minimal invasiveness while providing the sensitivity to detect biomolecular signatures in a physiological environment is challenging, in particular because the same waveguide must be employed for both delivering excitation light and collecting the resulting scattered photons. Here, a SERS-active neural probe based on a tapered optical fiber (TF) decorated with gold nanoislands (NIs) that can detect neurotransmitters down to the micromolar range is presented. To do this, a novel, nonplanar repeated dewetting technique to fabricate gold NIs with sub-10 nm gaps, uniformly distributed on the wide (square millimeter scale in surface area), highly curved surface of TF is developed. It is experimentally and numerically shown that the amplified broadband near-field enhancement of the high-density NIs layer allows for achieving a limit of detection in aqueous solution of 10-7  m for rhodamine 6G and 10-5  m for serotonin and dopamine through SERS at near-infrared wavelengths. The NIs-TF technology is envisioned as a first step toward the unexplored frontier of in vivo label-free plasmonic neural interfaces.
Repisalud
Publication Artículo científico (JournalArticle)

The Potential of Astrocytes as Immune Modulators in Brain Tumors

  • Priego, Neibla
  • Valiente, Manuel
The neuro-immune axis has emerged as a key aspect to understand the normal function of the Central Nervous System (CNS) as well as the pathophysiology of many brain disorders. As such, it may represent a promising source for novel therapeutic targets. Glial cells, and in particular the extensively studied microglia, play important roles in brain disorders. Astrocytes, in their reactive state, have been shown to positively and negatively modulate the progression of multiple CNS disorders. These seemingly opposing effects, might stem from their underlying heterogeneity, an aspect that has recently come to light. In this article we will discuss the link between reactive astrocytes and the neuro-immune axis with a perspective on their potential importance in brain tumors. Based on the gained knowledge from studies in other CNS disorders, reactive astrocytes are undoubtfully emerging as a key component of the neuro-immune axis, with ability to modulate both the innate and adaptive branches of the immune system. Lastly, we will discuss how we can exploit our improved understanding of the basic biology of astrocytes to further enhance the efficacy of emerging immune-based therapies in primary brain tumors and brain metastasis.
Repisalud
Publication Artículo científico (JournalArticle)

A clinically compatible drug-screening platform based on organotypic cultures identifies vulnerabilities to prevent and treat brain metastasis.

  • Zhu, Lucía
  • Retana, Diana
  • García-Gómez, Pedro
  • Álvaro-Espinosa, Laura
  • Priego, Neibla
  • Masmudi-Martín, Mariam
  • Yebra, Natalia
  • Miarka, Lauritz
  • Hernández-Encinas, Elena
  • Blanco-Aparicio, Carmen
  • Martínez, Sonia
  • Sobrino, Cecilia
  • Ajenjo, Nuria
  • Artiga, Maria-Jesus
  • Ortega-Paino, Eva
  • Torres-Ruiz, Raúl
  • Rodríguez-Perales, Sandra
  • Soffietti, Riccardo
  • Bertero, Luca
  • Cassoni, Paola
  • Weiss, Tobias
  • Muñoz, Javier
  • Sepúlveda, Juan Manuel
  • González-León, Pedro
  • Jiménez-Roldán, Luis
  • Moreno, Luis Miguel
  • Esteban, Olga
  • Pérez-Núñez, Ángel
  • Hernández-Laín, Aurelio
  • Toldos, Oscar
  • Ruano, Yolanda
  • Alcázar, Lucía
  • Blasco, Guillermo
  • Fernández-Alén, José
  • Caleiras, Eduardo
  • Lafarga, Miguel
  • Megías, Diego
  • Graña-Castro, Osvaldo
  • Nör, Carolina
  • Taylor, Michael D
  • Young, Leonie S
  • Varešlija, Damir
  • Cosgrove, Nicola
  • Couch, Fergus J
  • Cussó, Lorena
  • Desco, Manuel
  • Mouron, Silvana
  • Quintela Fandino, Miguel Angel
  • Weller, Michael
  • Pastor Fernandez, Joaquin
  • Valiente, Manuel
  • Zhu, Lucía
  • Retana, Diana
  • García-Gómez, Pedro
  • Álvaro-Espinosa, Laura
  • Priego, Neibla
  • Masmudi-Martín, Mariam
  • Yebra, Natalia
  • Miarka, Lauritz
  • Hernández-Encinas, Elena
  • Blanco-Aparicio, Carmen
  • Martínez, Sonia
  • Sobrino, Cecilia
  • Ajenjo, Nuria
  • Artiga, Maria-Jesus
  • Ortega-Paino, Eva
  • Torres-Ruiz, Raúl
  • Rodríguez-Perales, Sandra
  • Soffietti, Riccardo
  • Bertero, Luca
  • Cassoni, Paola
  • Weiss, Tobias
  • Muñoz, Javier
  • Sepúlveda, Juan Manuel
  • González-León, Pedro
  • Jiménez-Roldán, Luis
  • Moreno, Luis Miguel
  • Esteban, Olga
  • Pérez-Núñez, Ángel
  • Hernández-Laín, Aurelio
  • Toldos, Oscar
  • Ruano, Yolanda
  • Alcázar, Lucía
  • Blasco, Guillermo
  • Fernández-Alén, José
  • Caleiras, Eduardo
  • Lafarga, Miguel
  • Megías, Diego
  • Graña-Castro, Osvaldo
  • Nör, Carolina
  • Taylor, Michael D
  • Young, Leonie S
  • Varešlija, Damir
  • Cosgrove, Nicola
  • Couch, Fergus J
  • Cussó, Lorena
  • Desco, Manuel
  • Mouron, Silvana
  • Weller, Michael
We report a medium-throughput drug-screening platform (METPlatform) based on organotypic cultures that allows to evaluate inhibitors against metastases growing in situ. By applying this approach to the unmet clinical need of brain metastasis, we identified several vulnerabilities. Among them, a blood-brain barrier permeable HSP90 inhibitor showed high potency against mouse and human brain metastases at clinically relevant stages of the disease, including a novel model of local relapse after neurosurgery. Furthermore, in situ proteomic analysis applied to metastases treated with the chaperone inhibitor uncovered a novel molecular program in brain metastasis, which includes biomarkers of poor prognosis and actionable mechanisms of resistance. Our work validates METPlatform as a potent resource for metastasis research integrating drug-screening and unbiased omic approaches that is compatible with human samples. Thus, this clinically relevant strategy is aimed to personalize the management of metastatic disease in the brain and elsewhere.
Repisalud
Publication Artículo científico (JournalArticle)

Brain Microenvironment Heterogeneity: Potential Value for Brain Tumors.

  • Álvaro-Espinosa, Laura
  • de Pablos-Aragoneses, Ana
  • Valiente, Manuel
  • Priego, Neibla
Uncovering the complexity of the microenvironment that emerges in brain disorders is key to identify potential vulnerabilities that might help challenging diseases affecting this organ. Recently, genomic and proteomic analyses, especially at the single cell level, have reported previously unrecognized diversity within brain cell types. The complexity of the brain microenvironment increases during disease partly due to the immune infiltration from the periphery that contributes to redefine the brain connectome by establishing a new crosstalk with resident brain cell types. Within the rewired brain ecosystem, glial cell subpopulations are emerging hubs modulating the dialogue between the Immune System and the Central Nervous System with important consequences in the progression of brain tumors and other disorders. Single cell technologies are crucial not only to define and track the origin of disease-associated cell types, but also to identify their molecular similarities and differences that might be linked to specific brain injuries. These altered molecular patterns derived from reprogramming the healthy brain into an injured organ, might provide a new generation of therapeutic targets to challenge highly prevalent and lethal brain disorders that remain incurable with unprecedented specificity and limited toxicities. In this perspective, we present the most relevant clinical and pre-clinical work regarding the characterization of the heterogeneity within different components of the microenvironment in the healthy and injured brain with a special interest on single cell analysis. Finally, we discuss how understanding the diversity of the brain microenvironment could be exploited for translational purposes, particularly in primary and secondary tumors affecting the brain.
Repisalud
Publication Artículo científico (JournalArticle)

An Inbred Ecosystem that Supports Medulloblastoma.

  • de Pablos-Aragoneses, Ana
  • Valiente, Manuel
In a recent issue of Cell, Yao et al. use a unique genetic strategy to study sonic hedgehog-medulloblastoma. Their results reveal a complex network in the tumor microenvironment involving the trans-differentiation of cancer cells into astrocytes to fuel tumor growth.
Repisalud
Publication Artículo científico (JournalArticle)

Toward Plasmonic Neural Probes: SERS Detection of Neurotransmitters through Gold-Nanoislands-Decorated Tapered Optical Fibers with Sub-10 nm Gaps.

  • Zheng, Di
  • Pisano, Filippo
  • Collard, Liam
  • Balena, Antonio
  • Pisanello, Marco
  • Spagnolo, Barbara
  • Mach-Batlle, Rosa
  • Tantussi, Francesco
  • Carbone, Luigi
  • De Angelis, Francesco
  • Valiente, Manuel
  • de la Prida, Liset M
  • Ciracì, Cristian
  • De Vittorio, Massimo
  • Pisanello, Ferruccio
Integration of plasmonic nanostructures with fiber-optics-based neural probes enables label-free detection of molecular fingerprints via surface-enhanced Raman spectroscopy (SERS), and it represents a fascinating technological horizon to investigate brain function. However, developing neuroplasmonic probes that can interface with deep brain regions with minimal invasiveness while providing the sensitivity to detect biomolecular signatures in a physiological environment is challenging, in particular because the same waveguide must be employed for both delivering excitation light and collecting the resulting scattered photons. Here, a SERS-active neural probe based on a tapered optical fiber (TF) decorated with gold nanoislands (NIs) that can detect neurotransmitters down to the micromolar range is presented. To do this, a novel, nonplanar repeated dewetting technique to fabricate gold NIs with sub-10 nm gaps, uniformly distributed on the wide (square millimeter scale in surface area), highly curved surface of TF is developed. It is experimentally and numerically shown that the amplified broadband near-field enhancement of the high-density NIs layer allows for achieving a limit of detection in aqueous solution of 10  m for rhodamine 6G and 10  m for serotonin and dopamine through SERS at near-infrared wavelengths. The NIs-TF technology is envisioned as a first step toward the unexplored frontier of in vivo label-free plasmonic neural interfaces.
Repisalud
Publication Otros (Other)

Updating cancer research with patient-focused networks.

  • Valiente, Manuel
  • Ortega-Paino, Eva
Multidisciplinary patient-centered networks offer access to difficult-to-get samples and initiate projects from human material. Improving such networks to include 'living' samples could be transformative, not only for research but for clinical trial design, especially when focused on unmet clinical needs, such as brain metastasis.
Repisalud
Publication Artículo científico (JournalArticle)

Machine learning identifies experimental brain metastasis subtypes based on their influence on neural circuits.

  • Sanchez-Aguilera, Alberto
  • Masmudi-Martín, Mariam
  • Navas-Olive, Andrea
  • Baena, Patricia
  • Hernández-Oliver, Carolina
  • Priego, Neibla
  • Cordón-Barris, Lluís
  • Alvaro-Espinosa, Laura
  • García, Santiago
  • Martinez, Sonia
  • Lafarga, Miguel
  • Lin, Michael Z
  • Al-Shahrour, Fatima
  • Menendez de la Prida, Liset
  • Valiente, Manuel
A high percentage of patients with brain metastases frequently develop neurocognitive symptoms; however, understanding how brain metastasis co-opts the function of neuronal circuits beyond a tumor mass effect remains unknown. We report a comprehensive multidimensional modeling of brain functional analyses in the context of brain metastasis. By testing different preclinical models of brain metastasis from various primary sources and oncogenic profiles, we dissociated the heterogeneous impact on local field potential oscillatory activity from cortical and hippocampal areas that we detected from the homogeneous inter-model tumor size or glial response. In contrast, we report a potential underlying molecular program responsible for impairing neuronal crosstalk by scoring the transcriptomic and mutational profiles in a model-specific manner. Additionally, measurement of various brain activity readouts matched with machine learning strategies confirmed model-specific alterations that could help predict the presence and subtype of metastasis.
Repisalud
Publication Artículo científico antes de ser publicado, versión del autor (Preprint)

Universal scaling laws rule explosive growth in human cancers

  • Pérez-García, Víctor M
  • Calvo, Gabriel F
  • Bosque, Jesús J
  • León-Triana, Odelaisy
  • Jiménez, Juan
  • Perez-Beteta, Julián
  • Belmonte-Beitia, Juan
  • Zhu, Lucía
  • García-Gómez, Pedro
  • Sánchez-Gómez, Pilar
  • Hernandez-SanMiguel, Esther
  • Hortigüela, Rafael
  • Azimzade, Youness
  • Molina-García, David
  • Martinez, Álvaro
  • Acosta Rojas, Ángel
  • Ortiz de Mendivil, Ana
  • Vallette, Francois
  • Schucht, Philippe
  • Murek, Michael
  • Pérez-Cano, María
  • Albillo, David
  • Honguero Martínez, Antonio F
  • Jiménez Londoño, Germán A
  • Arana, Estanislao
  • García Vicente, Ana M
  • Valiente, Manuel
Most physical and other natural systems are complex entities composed of a large number of interacting individual elements. It is a surprising fact that they often obey the so-called scaling laws relating an observable quantity with a measure of the size of the system. Here we describe the discovery of universal superlinear metabolic scaling laws in human cancers. This dependence underpins increasing tumour aggressiveness, due to evolutionary dynamics, which leads to an explosive growth as the disease progresses. We validated this dynamic using longitudinal volumetric data of different histologies from large cohorts of cancer patients. To explain our observations we put forward increasingly-complex biologically-inspired mathematical models that captured the key processes governing tumor growth. Our models predicted that the emergence of superlinear allometric scaling laws is an inherently three-dimensional phenomenon. Moreover, the scaling laws thereby identified allowed us to define a set of metabolic metrics with prognostic value, thus providing added clinical utility to the base findings.
Repisalud
Publication Artículo científico (JournalArticle)

Animal models of brain metastasis.

  • Miarka, Lauritz
  • Valiente, Manuel
Modeling of metastatic disease in animal models is a critical resource to study the complexity of this multi-step process in a relevant system. Available models of metastatic disease to the brain are still far from ideal but they allow to address specific aspects of the biology or mimic clinically relevant scenarios. We not only review experimental models and their potential improvements but also discuss specific answers that could be obtained from them on unsolved aspects of clinical management.
Repisalud
Publication Artículo científico antes de ser publicado, versión del autor (Preprint)

Vascular co-option in brain metastasis.

  • García-Gómez, Pedro
  • Valiente, Manuel
Vascular co-option by brain metastasis-initiating cells has been demonstrated as a critical step in organ colonization. The physical interaction between the cancer cell and the endothelial cell is mediated by integrins and L1CAM and could be involved in aggressive growth but also latency and immune evasion. The key involvement of vascular co-option in brain metastasis has created an emerging field that aims to identify critical targets as well as effective inhibitors with the goal of preventing brain metastases.
Repisalud
Publication Artículo científico antes de ser publicado, versión del autor (Preprint)

Brain metastasis models: What should we aim to achieve better treatments?

  • Masmudi-Martín, M
  • Zhu, L
  • Sanchez-Navarro, M
  • Priego, N
  • Casanova-Acebes, M
  • Giralt, E
  • Masmudi-Martín, M.
  • Zhu, L.
  • Sanchez-Navarro, M.
  • Priego, N.
  • Casanova-Acebes, M.
  • Ruiz-Rodado, V
  • Giralt, E.
  • Valiente, Manuel
Brain metastasis is emerging as a unique entity in oncology based on its particular biology and, consequently, the pharmacological approaches that should be considered. We discuss the current state of modelling this specific progression of cancer and how these experimental models have been used to test multiple pharmacologic strategies over the years. In spite of pre-clinical evidences demonstrating brain metastasis vulnerabilities, many clinical trials have excluded patients with brain metastasis. Fortunately, this trend is getting to an end given the increasing importance of secondary brain tumors in the clinic and a better knowledge of the underlying biology. We discuss emerging trends and unsolved issues that will shape how we will study experimental brain metastasis in the years to come.
Repisalud
Publication Capítulo o parte de un libro (BookPart)

Brain Metastases Cell Partners and Tumor Microenvironment

  • García-Gómez, Pedro
  • Priego, Neibla
  • Álvaro-Espinosa, Laura
  • Valiente, Manuel
The microenvironment has emerged as a promising source of novel therapeutic applications in experimental models of brain metastasis. Our limited understanding of the complex brain ecosystem transformed by the presence of cancer cells includes key cell types that either promote or limit local progression of metastatic cells. Identification of the molecular networks regulating the crosstalk between cancer cells and the microenvironment but also within different brain resident and non-resident cell types surrounding the tumor is crucial to decipher the biology of colonization and subsequently to target key nodes with innovative and effective therapies.
Repisalud
Publication Artículo científico (JournalArticle)

Brain metastasis.

  • Boire, Adrienne
  • Brastianos, Priscilla K
  • Garzia, Livia
  • Valiente, Manuel
Brain metastasis, which commonly arises in patients with lung cancer, breast cancer and melanoma, is associated with poor survival outcomes and poses distinct clinical challenges. The brain microenvironment, with its unique cell types, anatomical structures, metabolic constraints and immune environment, differs drastically from microenvironments of extracranial lesions, imposing a distinct and profound selective pressure on tumour cells that, in turn, shapes the metastatic process and therapeutic responses. Accordingly, the study of brain metastasis could uncover new therapeutic targets and identify novel treatment approaches to address the unmet clinical need. Moreover, such efforts could provide insight into the biology of primary brain tumours, which face similar challenges to brain metastases of extracranial origin, and vice versa. However, the paucity of robust preclinical models of brain metastasis has severely limited such investigations, underscoring the importance of developing improved experimental models that holistically encompass the metastatic cascade and/or brain microenvironment. In this Viewpoint, we asked four leading experts to provide their opinions on these important aspects of brain metastasis biology and management.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Holographic Manipulation of Nanostructured Fiber Optics Enables Spatially-Resolved, Reconfigurable Optical Control of Plasmonic Local Field Enhancement and SERS

  • Collard, L.
  • Pisano, F.
  • Zheng, D.
  • Balena, Antonio
  • Kashif, M. F.
  • Pisanello, M.
  • D'Orazio, A.
  • Menéndez de la Prida, Liset
  • Ciracì, Cristian
  • Grande, M.
  • De Vittorio, M.
  • Pisanello, F.
Integration of plasmonic structures on step-index optical fibers is attracting interest for both applications and fundamental studies. However, the possibility to dynamically control the coupling between the guided light fields and the plasmonic resonances is hindered by the turbidity of light propagation in multimode fibers (MMFs). This pivotal point strongly limits the range of studies that can benefit from nanostructured fiber optics. Fortunately, harnessing the interaction between plasmonic modes on the fiber tip and the full set of guided modes can bring this technology to a next generation progress. Here, the intrinsic wealth of information of guided modes is exploited to spatiotemporally control the plasmonic resonances of the coupled system. This concept is shown by employing dynamic phase modulation to structure both the response of plasmonic MMFs on the plasmonic facet and their response in the corresponding Fourier plane, achieving spatial selective field enhancement and direct control of the probe's work point in the dispersion diagram. Such a conceptual leap would transform the biomedical applications of holographic endoscopic imaging by integrating new sensing and manipulation capabilities., L.C. and Fi.P. contributed equally to this work. M.D.V. and Fe.P. jointly supervised and are co-last authors of this work. L.C., D.Z., L.M.P., C.C., M.D.V., and Fe.P. acknowledge European Union’s Horizon 2020 Research and Innovation Program under Grant Agreement No. 828972. Fi.P., A.B., and Fe.P. acknowledge European Research Council under the European Union’s Horizon 2020 Research and Innovation Program under Grant Agreement No. 677683. Fi.P., M.D.V., and Fe.P. acknowledge European Union’s Horizon 2020 Research and Innovation Program under Grant Agreement No 101016787. M.P. and M.D.V. acknowledge European Research Council under the European Union’s Horizon 2020 Research and Innovation Program under Grant Agreement No. 692943. M.P., Fe.P., and M.D.V. acknowledge U.S. National Institutes of Health (Grant No. 1UF1NS108177-01). M.D.V. acknowledges U.S. National Institutes of Health (Grant No. U01NS094190).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Plasmonics on a Neural Implant: Engineering Light–Matter Interactions on the Nonplanar Surface of Tapered Optical Fibers

  • Pisano, F.
  • Kashif, M.F
  • Balena, Antonio
  • Pisanello, M.
  • De Angelis, F.
  • Menéndez de la Prida, Liset
  • Valiente, Manuel
  • D'Orazio, A.
  • De Vittorio, M.
  • Grande, M.
  • Pisanello, F.
Optical methods are driving a revolution in neuroscience. Ignited by optogenetic techniques, a set of strategies has emerged to control and monitor neural activity in deep brain regions using implantable photonic probes. A yet unexplored technological leap is exploiting nanoscale light-matter interactions for enhanced bio-sensing, beam-manipulation and opto-thermal heat delivery in the brain. To bridge this gap, we got inspired by the brain cells’ scale to propose a nano-patterned tapered-fiber neural implant featuring highly-curved plasmonic structures (30 μm radius of curvature, sub-50 nm gaps). We describe the nanofabrication process of the probes and characterize their optical properties. We suggest a theoretical framework using the interaction between the guided modes and plasmonic structures to engineer the electric field enhancement at arbitrary depths along the implant, in the visible/near-infrared range. We show that our probes can control the spectral and angular patterns of optical transmission, enhancing the angular emission and collection range beyond the reach of existing optical neural interfaces. Finally, we evaluate the application as fluorescence and Raman probes, with wave-vector selectivity, for multimodal neural applications. We believe our work represents a first step towards a new class of versatile nano-optical neural implants for brain research in health and disease., M.D.V., M.G., and Fe.P. jointly supervised and are co-last authors in this work. Fi.P., A.B., and Fe.P. acknowledge funding from the European Research Council under the European Union’s Horizon 2020 Research and Innovation Program under Grant Agreement No. 677683. F.D.A., L.M.d.l.P., M.V., M.D.V., and Fe.P. acknowledge funding from the European Union’s Horizon 2020 Research and Innovation Program under Grant Agreement No. 828972. Fi.P., M.D.V., and Fe.P. acknowledge that this project has received funding from the European Union’s Horizon 2020 Research and Innovation Program under Grant Agreement No. 101016787. M.P., Fe.P., and M.D.V. were funded by the U.S. National Institutes of Health (Grant No. 1UF1NS108177-01). Open access funding provided by Istituto Italiano di Tecnologia within the CRUI-CARE agreement
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Plasmonics on a Neural Implant: Engineering Light–Matter Interactions on the Nonplanar Surface of Tapered Optical Fibers

  • Pisano, F.
  • Kashif, M.F
  • Balena, Antonio
  • Pisanello, M.
  • De Angelis, F.
  • Menéndez de la Prida, Liset
  • Valiente, Manuel
  • D'Orazio, A.
  • De Vittorio, M.
  • Grande, M.
  • Pisanello, F.
Optical methods are driving a revolution in neuroscience. Ignited by optogenetic techniques, a set of strategies has emerged to control and monitor neural activity in deep brain regions using implantable photonic probes. A yet unexplored technological leap is exploiting nanoscale light-matter interactions for enhanced bio-sensing, beam-manipulation and opto-thermal heat delivery in the brain. To bridge this gap, we got inspired by the brain cells’ scale to propose a nano-patterned tapered-fiber neural implant featuring highly-curved plasmonic structures (30 μm radius of curvature, sub-50 nm gaps). We describe the nanofabrication process of the probes and characterize their optical properties. We suggest a theoretical framework using the interaction between the guided modes and plasmonic structures to engineer the electric field enhancement at arbitrary depths along the implant, in the visible/near-infrared range. We show that our probes can control the spectral and angular patterns of optical transmission, enhancing the angular emission and collection range beyond the reach of existing optical neural interfaces. Finally, we evaluate the application as fluorescence and Raman probes, with wave-vector selectivity, for multimodal neural applications. We believe our work represents a first step towards a new class of versatile nano-optical neural implants for brain research in health and disease., M.D.V., M.G., and Fe.P. jointly supervised and are co-last authors in this work. Fi.P., A.B., and Fe.P. acknowledge funding from the European Research Council under the European Union’s Horizon 2020 Research and Innovation Program under Grant Agreement No. 677683. F.D.A., L.M.d.l.P., M.V., M.D.V., and Fe.P. acknowledge funding from the European Union’s Horizon 2020 Research and Innovation Program under Grant Agreement No. 828972. Fi.P., M.D.V., and Fe.P. acknowledge that this project has received funding from the European Union’s Horizon 2020 Research and Innovation Program under Grant Agreement No. 101016787. M.P., Fe.P., and M.D.V. were funded by the U.S. National Institutes of Health (Grant No. 1UF1NS108177-01). Open access funding provided by Istituto Italiano di Tecnologia within the CRUI-CARE agreement
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Toward Plasmonic Neural Probes: SERS Detection of Neurotransmitters through Gold-Nanoislands-Decorated Tapered Optical Fibers with Sub-10 nm Gaps

  • Zheng, D.
  • Pisano, F.
  • Collard, L.
  • Balena, Antonio
  • Pisanello, M.
  • Spagnolo, B.
  • Mach-Batlle, R.
  • Tantussi, F.
  • Carbone, L.
  • De Angelis, F.
  • Valiente, M.
  • Menéndez de la Prida, Liset
  • Ciracì, Cristian
  • De Vittorio, M.
  • Pisanello, F.
Integration of plasmonic nanostructures with fiber-optics-based neural probes enables label-free detection of molecular fingerprints via surface-enhanced Raman spectroscopy (SERS), and it represents a fascinating technological horizon to investigate brain function. However, developing neuroplasmonic probes that can interface with deep brain regions with minimal invasiveness while providing the sensitivity to detect biomolecular signatures in a physiological environment is challenging, in particular because the same waveguide must be employed for both delivering excitation light and collecting the resulting scattered photons. Here, a SERS-active neural probe based on a tapered optical fiber (TF) decorated with gold nanoislands (NIs) that can detect neurotransmitters down to the micromolar range is presented. To do this, a novel, nonplanar repeated dewetting technique to fabricate gold NIs with sub-10 nm gaps, uniformly distributed on the wide (square millimeter scale in surface area), highly curved surface of TF is developed. It is experimentally and numerically shown that the amplified broadband near-field enhancement of the high-density NIs layer allows for achieving a limit of detection in aqueous solution of 10 m for rhodamine 6G and 10 m for serotonin and dopamine through SERS at near-infrared wavelengths. The NIs-TF technology is envisioned as a first step toward the unexplored frontier of in vivo label-free plasmonic neural interfaces., M.D.V. and Fe.P. contributed equally to this work and are co-last-authors. D.Z., Li.C., R.M.-B., A.B., C.C., F.T., F.D.A., L.M.P., M.V., M.D.V., and Fe.P. acknowledge funding from the European Union’s Horizon 2020 Research and Innovation Program under Grant Agreement No. 828972. Fi.P., A.B., B.S., and Fe.P. acknowledge funding from the European Research Council under the European Union’s Horizon 2020 Research and Innovation Program under Grant Agreement No. 677683. Lu.C. acknowledges financial support by the Italian Ministry of Economic Development through the Project “GENESI”-Development of innovative radiopharmaceuticals and biomarkers for the diagnosis of tumors of the male and female reproductive apparatus (cod. F/180003/01-03/X43, Call MISE “Intelligent Factory, Agri food and Life Sciences”). Fi.P., M.D.V., and Fe.P. acknowledge that this project has received funding from the European Union’s Horizon 2020 Research and Innovation Program under Grant Agreement No. 101016787. M.P., Fe.P., and M.D.V. were funded by the U.S. National Institutes of Health (Grant No. 1UF1NS108177-01).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Vibrational fiber photometry: label-free and reporter-free minimally invasive Raman spectroscopy deep in the mouse brain

  • Pisano, Filippo
  • Masmudi-Martín, Mariam
  • Andriani, Maria Samuela
  • Cid, Elena
  • Kazemzadeh, Mohammadrahim
  • Pisanello, Marco
  • Balena, Antonio
  • Collard, Liam
  • Parras, Teresa Jurado
  • Bianco, Marco
  • Baena, Patricia
  • Tantussi, Francesco
  • Grande, Marco
  • Sileo, Leonardo
  • Gentile, Francesco
  • De Angelis, Francesco
  • De Vittorio, Massimo
  • Menéndez de la Prida, Liset
  • Valiente, Manuel
  • Pisanello, Ferruccio
Optical approaches to monitor neural activity are transforming neuroscience, owing to a fast-evolving palette of genetically encoded molecular reporters. However, the field still requires robust and label-free technologies to monitor the multifaceted biomolecular changes accompanying brain development, aging or disease. Here, we have developed vibrational fiber photometry as a low-invasive method for label-free monitoring of the biomolecular content of arbitrarily deep regions of the mouse brain in vivo through spontaneous Raman spectroscopy. Using a tapered fiber probe as thin as 1 µm at its tip, we elucidate the cytoarchitecture of the mouse brain, monitor molecular alterations caused by traumatic brain injury, as well as detect markers of brain metastasis with high accuracy. We view our approach, which introduces a deep learning algorithm to suppress probe background, as a promising complement to the existing palette of tools for the optical interrogation of neural function, with application to fundamental and preclinical investigations of the brain and other organs., This work is dedicated to the memory of Prof. Marco Grande and to his legacy of scientific excellence and human kindness. M.M.-M, E.C., T.J.P., A.B., F.T., L.C., M.D.V., F.D.A., L.M.P., M.V. and F. Pisanello acknowledge funding from the European Union’s Horizon 2020 FET-Open Programme project NANOBRIGHT under grant agreement 828972. F. Pisano, M.B., M.P., L.S., M.D.V. and F. Pisanello acknowledge funding from the European Union’s Horizon 2020 Research and Innovation Programme project DEEPER under grant agreement 101016787. This research received support from the European Community under the program Horizon 2020 project ProID under grant agreement 964363. F. Pisano acknowledges funding from PARD 2024 from the University of Padua. M.M.-M. acknowledges funding from a postdoctoral grant (2023) from the Scientific Foundation of the Spanish Association Against Cancer. F.G. acknowledges funding from Associazione Italiana per la Ricerca sul Cancro – AIRC IG 2021 ID 25656. L.C., M.D.V. and F. Pisanello acknowledge funding from the Project 'RAISE (Robotics and AI for Socio-economic Empowerment)' (code ECS00000035) funded by European Union – NextGenerationEU PNRR MUR – M4C2 – Investimento 1.5 – Avviso 'Ecosistemi dell’Innovazione' CUP J33C22001220001. A.B. acknowledges funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant agreement (101106602)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

MIF-Induced CD74+ Microglia and Macrophages Promote Progression of Brain Metastasis and Are Clinically Relevant across Central Nervous System Disorders

  • Alvaro-Espinosa, Laura
  • Marquez-Galera, Angel
  • Priego, Neibla
  • García-Calvo, Virginia
  • Perea-García, Maria
  • Hernandez-Oliver, Carolina
  • Retana, Diana
  • Sanchez, Oliva
  • Pablos-Aragoneses, Ana de
  • García-Gómez, Pedro
  • Graña-Castro, Osvaldo
  • Lapuente-Santana, Óscar
  • Serrano-Ron, Laura
  • Al-Shahrour, Fatima
  • Cayuela López, Ana
  • Peset, Isabel
  • Megías, Diego
  • Ola, Mihaela
  • Varešlija, Damir
  • Young, Leonie S.
  • Martí-Mateos, Yolanda
  • Enríquez, Jose A.
  • Hernández-Encinas, Elena
  • Blanco-Aparicio, Carmen
  • Soengas, María S.
  • Bernhagen, Juergen
  • Antón-Fernández, Alejandro
  • Ávila, Jesús
  • Marchena, Miguel A.
  • Torres, Maximiliano
  • Castro Soubriet, Fernando de
  • Márquez-Ropero, Mar
  • Sierra, Amanda
  • López-Atalaya, José P.
  • Valiente, Manuel
  • RENACER Group
The upregulation of CD74, a chaperone involved in MHC-II antigen processing, has been mostly interpreted as indicative of antigen presentation in multiple brain disorders. However, CD74 expression has also been described in cancer cells across multiple tumor types and in the tumor microenvironment, notably in glioma. In this study, we found that the presence of CD74+ microglia/macrophages, which was induced by increased levels of interferon γ in brains affected by metastases, did not relate to its canonical pathway. Instead, the alternative function of CD74 as a cytokine receptor was pivotal. Proliferating cancer cells produced high levels of the ligand migration inhibitory factor (MIF) that bound the CD74 receptor and induced its translocation to the nucleus where it activated an NF-κB-dependent program that promoted metastatic progression. In patients, a CD74 signature was associated with more aggressive progression of brain metastatic disease, although it had no clinical correlation with the matched primary tumor. Interestingly, a pan-disease noncanonical and clinically relevant signature derived from the CD74+ myeloid population was identified that occurred in additional brain disorders, including Alzheimer's disease and multiple sclerosis. The brain-penetrant drug ibudilast, which prevents the binding of MIF to CD74, decreased brain metastasis in experimental models in vivo and in patient-derived organotypic cultures ex vivo in a primary tumor-agnostic manner. These findings suggest that MIF/CD74-induced reprogramming of myeloid cells in brain disorders is a vulnerability that could be exploited therapeutically against brain metastases and possibly other brain disorders., We thank all members of the Brain Metastasis Group for critical discussion of the manuscript; the CNIO Core Facilities for their excellent assistance; and Estefanía Sánchez-Jiménez (F. de Castro laboratory at Instituto Cajal-CSIC) and the staff at the Animal Facilities of the Instituto Cajal-CSIC for their extraordinary help with animals of the cuprizone demyelinating murine model of multiple sclerosis. Special thanks to patients and their families who donated valuable materials to RENACER and all site personnel, investigators, funders, and industry partners who supported the generation of the data within this study. Postmortem cortical brain tissue blocks from patients with multiple sclerosis and controls, as well as the associated clinical and neuropathologic data, were supplied by the Multiple Sclerosis & Parkinson’s Tissue Bank at Imperial College (London, United Kingdom), funded by the Multiple Sclerosis Society of Great Britain and Northern Ireland, registered charity 207495. We thank J. Massagué (MSKCC) for some of the BrM cell lines. This study was funded by La Marató (201906-30-31-32; M. Valiente), MICIU (SAF2017-89643-R, SAF2014-57243-R, and SAF2015-62547-ERC to M. Valiente; PID2022-143110OB-I00 and RED2024-153909-E to F. de Castro), H2020-FETOPEN (828972; M. Valiente), Bristol Myers Squibb MRA Young Investigator Award (498103; M. Valiente), Cancer Research Institute (Clinic and Laboratory Integration Program CRI Award 2018; 54545; M. Valiente), LAB AECC 2019 (LABAE19002VALI; M. Valiente), AECC Coordinados (PRYCO234528VALI; M. Valiente), ERC CoG (864759; M. Valiente), and ERANET-TRANSCAN-3 (TRANSCAN2021-203; M. Valiente) with funds from Instituto de Salud Carlos III/NextGenerationEU/PRTR (AC20/00114) and FC AECC (TRNSC213878VALI), CaixaResearch Health (HR23-00051; M. Valiente), MINECO-Ramón y Cajal (RYC-2013-13365; M. Valiente), MICIU/AEI/10.13039/501100011033 and ERDF (RTI2018-102260-B-I00; J.P. Lopez-Atalaya), Generalitat Valenciana (PROMETEO/2020/007; J.P. Lopez-Atalaya), Ramón Areces Foundation (CIVP20S10662 to E. Ortega-Paino/M.-J. Artiga; CIVP19S8163 to M. Valiente; and CIVP19A5917 to F. de Castro), Spanish Ministry of Science and Innovation Competitiveness MCIN/AEI/10.13039/501100011033 and “ERDF A way of making Europe” (RTI2018-099267-B-I00 and PID2022-136698OB-I00; A. Sierra), Basque Government grants (IT1473-22; A. Sierra), Alzheimer Association award (AARG-NTF-24-1304352; A. Sierra), Breast Cancer Ireland (18239A01; L.S. Young), Research Ireland (19/FFP/6443; L.S. Young, 20/FFP-P/8597; D. Varešlija, and 23/SPP/11783; L.S. Young, D. Varešlija), Breast Cancer Now (2021 July PCC1460; L.S. Young, D. Varešlija, 2019 Aug SF1310 with the generous support of Walk the Walk; D. Varešlija), MCIN/AEI/10.13039/501100011033 and the European Union “NextGenerationEU”/Plan de Recuperación Transformación y Resiliencia, PRTR (RTI2018-099357-B-I00, PID2021-1279880B, and TED2021-131611B-I00; J.A. Enríquez), CIBERFES (CB16/10/00282; J.A. Enríquez), Foundation Leducq (17CVD04; J.A. Enríquez), MCIN/AEI/10 PID2023-147213OB-I00 (M.S. Soengas), ERC-Advanced Grant 884699 (M.S. Soengas), La Caixa International PhD Program Fellowship-Marie Sklodowska-Curie (LCF/BQ/DI17/11620028; P. García-Gómez and LCF/BQ/DI19/11730044; A. de Pablos-Aragoneses), AECC postdoctoral fellowship (POSTD19016PRIE; N. Priego), MINECO-Severo Ochoa PhD Fellowship (BES-2017-081995; L. Alvaro-Espinosa), FPI-Severo Ochoa Fellowship PRE2018-083478 awarded by MICIU/AEI/10.13039/501100011033, and European Social Funds (FSE invierte en tu futuro; Y. Martí-Mateos). M. Valiente is an EMBO YIP member (4053). The CNIC is supported by the Instituto de Salud Carlos III, the Ministerio de Ciencia, Innovación y Universidades, and the Pro CNIC Foundation and is a Severo Ochoa Center of Excellence (grant CEX2020-001041-S funded by MICIU/AEI/10.13039/501100011033). The Instituto de Neurociencias is a “Centre of Excellence Severo Ochoa” (CEX2021-001165-S funded by MCIU/AEI/10.13039/501100011033). CNIO is supported by the ISCIII, the Ministerio de Ciencia e Innovación, and is a Severo Ochoa Center of Excellence (SEV-2015-0510)., With funding from the Spanish government through the "Severo Ochoa Centre of Excelence" accreditation (CEX2020-001041-S), With funding from the Spanish government through the "Severo Ochoa Centre of Excelence" accreditation (CEX2021-001165-S), Peer reviewed